Immune Pharmaceuticals Inc (IMNP) financial statements (2021 and earlier)

Company profile

Business Address 1 BRIDGE PLAZA N, SUITE 270
FORT LEE, NJ 07024
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
12/31/2012
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments705700
Cash and cash equivalents705700
Restricted cash and investments 00001
Prepaid expense and other current assets0
Other current assets00000
Total current assets:715701
Noncurrent Assets
Property, plant and equipment 00000
Intangible assets, net (including goodwill)63334
Intangible assets, net (excluding goodwill)63334 
Regulated entity, other noncurrent assets 0    
Restricted cash and investments    0 
Deferred costs     0
Other noncurrent assets000  
Other undisclosed noncurrent assets1515282828 
Total noncurrent assets:22183131310
TOTAL ASSETS:29193638321
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities665692
Accounts payable442151
Accrued liabilities233440
Employee-related liabilities   010
Taxes payable   00 
Debt3312612
Derivative instruments and hedges, liabilities  0   
Liability for uncertainty in income taxes   00 
Due to related parties00 00 
Deferred revenue and credits     0
Other undisclosed current liabilities   (1)(5)(7)
Total current liabilities:9967118
Noncurrent Liabilities
Long-term debt and lease obligation11323 
Long-term debt, excluding current maturities11323 
Capital lease obligations 00   
Liabilities, other than long-term debt461711117
Deferred revenue and credits     7
Deferred tax liabilities, net46111111 
Derivative instruments and hedges, liabilities  7   
Other undisclosed noncurrent liabilities   01 
Total noncurrent liabilities:672013157
Total liabilities:151727202615
Temporary equity, carrying amount  2   
Stockholders' equity
Stockholders' equity attributable to parent, including:1438185(14)
Common stock000000
Treasury stock, value     (0)
Additional paid in capital12798716328237
Accumulated other comprehensive loss     (1)
Accumulated deficit(114)(96)(63)(46)(22)(269)
Warrants and rights outstanding     19
Other undisclosed stockholders' equity attributable to parent   1  
Total stockholders' equity:1438185(14)
TOTAL LIABILITIES AND EQUITY:29193638321

Income statement (P&L) ($ in millions)

12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
12/31/2012
Revenues   008
Revenue, net     8
Cost of revenue (13)   (1)
Cost of goods and services sold     (1)
Gross profit: (13) 007
Operating expenses(12)(15)(16)(17)(9)(9)
Other operating income (expense), net   (7)32
Other expenses   (0)02
Other undisclosed operating income (loss)   7(3)(1)
Operating loss:(12)(27)(16)(16)(9)(1)
Nonoperating expense(0)(0)(0)  (3)
Debt instrument, convertible, beneficial conversion feature     (4)
Other nonoperating expense(0)(0)(0)   
Interest and debt expense(6)(2)(1)(3)(0)(1)
Other undisclosed income (loss) from continuing operations before equity method investments, income taxes(2)(9)(0)(4)43
Loss from continuing operations before income taxes:(20)(38)(17)(24)(6)(3)
Income tax expense (benefit)25  (0)(0)
Net loss attributable to parent:(18)(33)(17)(24)(6)(3)
Other undisclosed net loss available to common stockholders, basic(7)(8)(7)(1)(1)(4)
Net loss available to common stockholders, basic:(25)(41)(24)(24)(7)(6)
Convertible preferred dividends    (1)(4)
Net loss available to common stockholders, diluted:(25)(41)(24)(24)(8)(10)

Comprehensive Income ($ in millions)

12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
12/31/2012
Net loss:(18)(33)(17)(24)(6)(3)
Comprehensive loss:(18)(33)(17)(24)(6)(3)
Other undisclosed comprehensive loss, net of tax, attributable to parent     (0)
Comprehensive loss, net of tax, attributable to parent:(18)(33)(17)(24)(6)(3)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: